Molecular Weight(MW): 159.1
Allopurinol Sodium is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.
Purity & Quality Control
Choose Selective ROS Inhibitors
|Description||Allopurinol Sodium is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.|
|In vitro||DMSO||32 mg/mL (201.13 mM)|
|Water||32 mg/mL (201.13 mM)|
|Ethanol||2 mg/mL (12.57 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02661035||Recruiting||Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Lymphoblastic Lymphoma|Burkitt''s Lymphoma|Non-Hodgkin''s Lymphoma|Multiple Myeloma|Myeloproliferative Syndromes|Hematological Diseases||Masonic Cancer Center University of Minnesota||March 9 2017||Phase 2|
|NCT02579096||Recruiting||Gout|Chronic Kidney Diseases||VA Office of Research and Development||March 6 2017||Phase 4|
|NCT03336203||Recruiting||Gout|CKD Stage 1-4|SUA Level (>8 mg/dL; 480 µmol/L)||Medical Practice Prof D. Ivanov|Dr. T. Bevzenko Dr. O. Synyachenko Dr. I. Golovach||October 30 2017||Phase 4|
|NCT02888054||Completed||Healthy||Ardea Biosciences Inc.||August 30 2016||Phase 1|
|NCT03076684||Recruiting||Hyperuricemia||University of Missouri-Columbia||March 3 2017||Early Phase 1|
|NCT01564277||Terminated||Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|de Novo Myelodysplastic Syndromes|Noncontiguous Stage II Adult Burkitt Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Stage I Adult Burkitt Lymphoma|Stage III Adult Burkitt Lymphoma|Stage IV Adult Burkitt Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia||Roswell Park Cancer Institute|National Cancer Institute (NCI)||September 29 2011||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.